Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

NCT01987375 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped logistics

Conditions

Head and Neck Cancer

Interventions

DRUG: Cetuximab-IRDye800

Sponsor

Eben Rosenthal